Searching News Database: TAXUS ATLAS trial
HSMN NewsFeed - 22 Sep 2010
Long-Term Data Show Advantages for TAXUS(R) Liberte(R) Stent in Small Vessels and Long Lesions
Long-Term Data Show Advantages for TAXUS(R) Liberte(R) Stent in Small Vessels and Long Lesions
HSMN NewsFeed - 21 Dec 2007
TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients
TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients
HSMN NewsFeed - 26 Oct 2006
TAXUS(R) stents demonstrate excellent efficacy and safety in studies presented at TCT 2006
TAXUS(R) stents demonstrate excellent efficacy and safety in studies presented at TCT 2006
HSMN NewsFeed - 25 Oct 2006
Safety and Efficacy Benefits of Next-Generation TAXUS(R) Liberte(TM) Stent Sustained at Twelve Months
Safety and Efficacy Benefits of Next-Generation TAXUS(R) Liberte(TM) Stent Sustained at Twelve Months
HSMN NewsFeed - 16 May 2006
TAXUS ATLAS Trial Supports Superior Deliverability and Proven Outcomes of TAXUS(R) Liberte(TM) Stent System
TAXUS ATLAS Trial Supports Superior Deliverability and Proven Outcomes of TAXUS(R) Liberte(TM) Stent System
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!